Mycoplasma pneumonia is caused by infection of Mycoplasma pneumoniae, and is a frequently occurring infectious disease transmitted from children to young adults. Macrolides are recommended as first-line drugs, minocycline (MINO) and tosufloxacin (TFLX) are used for the second-line drugs. In this study, we investigated the factors affecting the treatment period of mycoplasma pneumonia.
We compared the effects of azithromycin (AZM), TFLX and MINO. The duration from hospitalization to defervescence was shorter in the MINO group than in the TFLX group. We then attempted to identify the factors that affect the treatment period of mycoplasma pneumonia. Patients who were treated in accordance with the Guidelines for the Management of Respiratory Infectious Diseases in Children in Japan 2011 (Guideline) showed shorter duration of fever and disease duration as compared with patients who were not treated in accordance with the guidelines.
In the case macrolides are ineffective, quickly switching to other drugs showed higher efficiency. In the light of these results, as treatment is carried out in accordance with the Guidelines, the disease and fever periods are shortened, and prolonged treatment in children could be prevented. These results also suggest that MINO is more effective for the treatment of mycoplasma pneumonia than TFLX.
